Soluble T cell receptors: Novel immunotherapies

Current Opinion in Pharmacology

Volumn 5, Issue 4 SPEC. ISS., 2005, Pages 438-443

  Molloy, Peter E ^a   Sewell, Andrew K ^b   Jakobsen, Bent K ^a  

^a Avidex Limited   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; LEUKOCYTE ANTIBODY; LEUKOCYTE ANTIGEN; RADIOISOTOPE; T LYMPHOCYTE RECEPTOR; TOXIN; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ALLERGIC ENCEPHALOMYELITIS; ALLERGY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER; CELL TYPE; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; LUNG METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN TARGETING; RECEPTOR AFFINITY; REVIEW; SOMATIC MUTATION; T CELL LYMPHOMA; VACCINATION; VIRUS INFECTION;

EID: 21644475907     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.02.004     Document Type: Review

References (49)

1. G. Kohler C. Milstein Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 1975 495-497
2. J. Osbourn L. Jermutus A. Duncan Current methods for the generation of human antibodies for the treatment of autoimmune diseases Drug Discov Today 8 2003 845-851
3. A. Casadevall E. Dadachova L.A. Pirofski Passive antibody therapy for infectious diseases Nat Rev Microbiol 2 2004 695-703
4. O.H. Brekke I. Sandlie Therapeutic antibodies for human diseases at the dawn of the twenty-first century Nat Rev Drug Discov 2 2003 52-62
5. F.S. Wong C.A. Janeway Insulin-dependent diabetes mellitus and its animal models Curr Opin Immunol 11 1999 643-647
6. B. Laugel J.M. Boulter N. Lissin A. Vuidepot Y. Li E. Gostick L.E. Crotty D.C. Douek J. Hemelaar D.A. Price et al. Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition J Biol Chem 280 2005 1882-1892
7. L. Novellino C. Castelli G. Parmiani A listing of human tumor antigens recognized by T cells: March 2004 update Cancer Immunol Immunother 54 2005 187-207
8. D.H. Fremont W.A. Rees H. Kozono Biophysical studies of T-cell receptors and their ligands Curr Opin Immunol 8 1996 93-100
9. F. Pecorari A.C. Tissot A. Pluckthun Folding, heterodimeric association and specific peptide recognition of a murine alphabeta T-cell receptor expressed in Escherichia coli J Mol Biol 285 1999 1831-1843
10. C.A. Leath III J.T. Douglas D.T. Curiel R.D. Alvarez Single-chain antibodies: A therapeutic modality for cancer gene therapy (review) Int J Oncol 24 2004 765-771
11. B.E. Willcox G.F. Gao J.R. Wyer C.A. O'Callaghan J.M. Boulter E.Y. Jones P.A. van der Merwe J.I. Bell B.K. Jakobsen Production of soluble alphabeta T-cell receptor heterodimers suitable for biophysical analysis of ligand binding Protein Sci 8 1999 2418-2423
12. B.E. Willcox G.F. Gao J.R. Wyer J.E. Ladbury J.I. Bell B.K. Jakobsen P.A. van der Merwe TCR binding to peptide-MHC stabilizes a flexible recognition interface Immunity 10 1999 357-365
13. J.R. Wyer B.E. Willcox G.F. Gao U.C. Gerth S.J. Davis J.I. Bell P.A. van der Merwe B.K. Jakobsen T cell receptor and coreceptor CD8 alphaalpha bind peptide-MHC independently and with distinct kinetics Immunity 10 1999 219-225
14. J.M. Boulter M. Glick P.T. Todorov E. Baston M. Sami P. Rizkallah B.K. Jakobsen Stable, soluble T-cell receptor molecules for crystallization and therapeutics Protein Eng 16 2003 707-711
15. M.M. Davis J.J. Boniface Z. Reich D. Lyons J. Hampl B. Arden Y. Chien Ligand recognition by alpha beta T cell receptors Annu Rev Immunol 16 1998 523-544
16. R.A. Subbramanian C. Moriya K.L. Martin F.W. Peyerl A. Hasegawa A. Naoi H. Chhay P. Autissier D.A. Gorgone M.A. Lifton et al. Engineered T-cell receptor tetramers bind MHC-peptide complexes with high affinity Nat Biotechnol 22 2004 1429-1434
17. D. Mason A very high level of crossreactivity is an essential feature of the T-cell receptor Immunol Today 19 1998 395-404
18. K.F. Card S.A. Price-Schiavi B. Liu E. Thomson E. Nieves H. Belmont J. Builes J.A. Jiao J. Hernandez J. Weidanz et al. A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity Cancer Immunol Immunother 53 2004 345-357
19. M. Epel J.D. Ellenhorn D.J. Diamond Y. Reiter A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells Cancer Immunol Immunother 51 2002 565-573
20. Gascoigne NR, Zal T, Alam SM: T-cell receptor binding kinetics in T-cell development and activation. Expert Rev Mol Med 2001, 12 Feburary [URL: http://www-ermm.cbcu.cam.ac.uk/01002502h.htm].
21. D.P. McGregor P.E. Molloy C. Cunningham W.J. Harris Spontaneous assembly of bivalent single chain antibody fragments in Escherichia coli Mol Immunol 31 1994 219-226
22. P.D. Holler P.O. Holman E.V. Shusta S. O'Herrin K.D. Wittrup D.M. Kranz In vitro evolution of a T cell receptor with high affinity for peptide/ MHC Proc Natl Acad Sci USA 97 2000 5387-5392
23. M.C. Kieke E.V. Shusta E.T. Boder L. Teyton K.D. Wittrup D.M. Kranz Selection of functional T cell receptor mutants from a yeast surface-display library Proc Natl Acad Sci USA 96 1999 5651-5656
24. L.K. Chlewicki P.D. Holler B.C. Monti M.R. Clutter D.M. Kranz High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3 J Mol Biol 346 2005 223-239
25. Y. Li R. Moysey P.E. Molloy A. Vuidepot T. Mahon E. Baston S. Dunn N. Liddy J. Jacob B.K. Jakobsen J.M. Boulter Directed evolution of human T-cell receptors with picomolar affinity by phage display Nat Biotechnol 23 2005 349-354
26. R.H. Vonderheide Telomerase as a universal tumor-associated antigen for cancer immunotherapy Oncogene 21 2002 674-679
27. M.H. Andersen L.O. Pedersen B. Capeller E.B. Brocker J.C. Becker P. Thor Straten Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients Cancer Res 61 2001 5964-5968
28. I. Bellantuono L. Gao S. Parry S. Marley F. Dazzi J. Apperley J.M. Goldman H.J. Stauss Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL Blood 100 2002 3835-3837
29. C. Halin V. Gafner M.E. Villani L. Borsi A. Berndt H. Kosmehl L. Zardi D. Neri Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha Cancer Res 63 2003 3202-3210
30. J.S. Dela Cruz T.H. Huang M.L. Penichet S.L. Morrison Antibody-cytokine fusion proteins: Innovative weapons in the war against cancer Clin Exp Med 4 2004 57-64
31. V.K. Tuohy M. Yu L. Yin J.A. Kawczak J.M. Johnson P.M. Mathisen B. Weinstock-Guttman R.P. Kinkel The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis Immunol Rev 164 1998 93-100
32. M.E. Pauza H. Neal A. Hagenbaugh H. Cheroutre D. Lo T-cell production of an inducible interleukin-10 transgene provides limited protection from autoimmune diabetes Diabetes 48 1999 1948-1953
33. P. Zaccone J. Phillips I. Conget R. Gomis K. Haskins A. Minty K. Bendtzen A. Cooke F. Nicoletti Interleukin-13 prevents autoimmune diabetes in NOD mice Diabetes 48 1999 1522-1528
34. P.C. Stokkers D.W. Hommes New cytokine therapeutics for inflammatory bowel disease Cytokine 28 2004 167-173
35. S.M. Thirdborough J.N. Radcliffe P.S. Friedmann F.K. Stevenson Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma Cancer Res 62 2002 1757-1760
36. S.L. Lambert C.Y. Okada R. Levy TCR vaccines against a murine T cell lymphoma: A primary role for antibodies of the IgG2c class in tumor protection J Immunol 172 2004 929-936
37. V. Kumar E. Coulsell B. Ober G. Hubbard E. Sercarz E.S. Ward Recombinant T cell receptor molecules can prevent and reverse experimental autoimmune encephalomyelitis: Dose effects and involvement of both CD4 and CD8 T cells J Immunol 159 1997 5150-5156
38. M.A. Roskrow N. Suzuki Y. Gan J.W. Sixbey C.Y. Ng S. Kimbrough M. Hudson M.K. Brenner H.E. Heslop C.M. Rooney Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease Blood 91 1998 2925-2934
39. C.M. Rooney C.A. Smith C.Y. Ng S.K. Loftin J.W. Sixbey Y. Gan D.K. Srivastava L.C. Bowman R.A. Krance M.K. Brenner H.E. Heslop Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients Blood 92 1998 1549-1555
40. C.M. Rooney C.A. Smith C.Y. Ng S. Loftin C. Li R.A. Krance M.K. Brenner H.E. Heslop Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation Lancet 345 1995 9-13
41. E.A. Walter P.D. Greenberg M.J. Gilbert R.J. Finch K.S. Watanabe E.D. Thomas S.R. Riddell Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor N Engl J Med 333 1995 1038-1044
42. H.W. Kessels M.C. Wolkers M.D. van den Boom M.A. van der Valk T.N. Schumacher Immunotherapy through TCR gene transfer Nat Immunol 2 2001 957-961
43. T.N. Schumacher T-cell-receptor gene therapy Nat Rev Immunol 2 2002 512-519
44. T. Stanislawski R.H. Voss C. Lotz E. Sadovnikova R.A. Willemsen J. Kuball T. Ruppert R.L. Bolhuis C.J. Melief C. Huber et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer Nat Immunol 2 2001 962-970
45. P.D. Holler A.R. Lim B.K. Cho L.A. Rund D.M. Kranz CD8(-) T cell transfectants that express a high affinity T cell receptor exhibit enhanced peptide-dependent activation J Exp Med 194 2001 1043-1052
46. E. Erlandsson K. Andersson A. Cavallin A. Nilsson U. Larsson-Lorek U. Niss A. Sjoberg M. Wallen-Ohman P. Antonsson B. Walse G. Forsberg Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy J Mol Biol 333 2003 893-905
47. P.A. Davol J.A. Smith N. Kouttab G.J. Elfenbein L.G. Lum Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice Clin Prostate Cancer. 3 2004 112-121
48. Y. Gao D. Xiong M. Yang H. Liu H. Peng X. Shao Y. Xu C. Xu D. Fan L. Qin et al. Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody Leukemia 18 2004 513-520
49. A. Lev R. Noy K. Oved H. Novak D. Segal P. Walden D. Zehn Y. Reiter Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo Proc Natl Acad Sci USA 101 2004 9051-9056